Biotech Market Dynamics
The biotech sector experienced unprecedented declines, with stocks plummeting 64% from February 2021 to June 2022. Many companies traded below their cash reserves, indicating a market perception that their R&D was worthless. Despite this bleak outlook, opportunities emerged in early commercial companies that were close to profitability, highlighting a stark contrast in market valuations.In this clip
From this podcast
Capital Allocators – Inside the Institutional Investment Industry
Andy Acker - Empty Rooms: Investing in Biotech at Janus Henderson (Capital Allocators, EP.274)
Related Questions